Product Features Long-acting GIP/GLP-1 receptor agonist Specifications 2.5mg/5mg, two per box Shape Injection Ingredients Tirzepatide additives: Disodium hydrogen phosphate heptahydrate 0.7mg, Sodium chloride 4.1mg, Hydrochloric acid (appropriate amount), Sodium hydroxide (appropriate amount) Functional indications Efficacy or Effect: Type 2 Diabetes
According to the 5x half-life rule, the concentration of semaglutide in the blood is as follows: Clinical studies on semaglutide clearance In pharmacokinetic studies, semaglutides terminal half-life was measured at around 145 to 168 hours, or roughly seven days
The dual activation in Tirzepatide produces roughly 21% weight loss
Among adults ages 65 and over, 8% say they have taken a GLP-1 medication for a chronic condition, while just 1% say they have taken these drugs only to lose weight, which may be a reflection of Medicares lack of coverage for prescription drugs used for weight loss